masila - Thanks for the link to the Novartis article. I'm looking forward to the prospects of going up against a drug that is priced at $64,000 a year with a patent life of just 6 years. If the BoM trial results come in anywhere close to the post hock analysis of ASSURE and a price tag of $4000 to $5000 per year with a patent life of 16 years(to 2034) then we could certainly have a mega block buster in our hands. If there is any cancer benefit to apabetalone then it would seem everyone's potential sales numbers are dramatically low. There is certainly speculation in my words here but my excitement is definitely warranted. We have just 9 months or so left until the Top Line results should be out.

At the risk of plagiarizing Bear, Go RVX Go.

dyodd

tada